|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001483,
umls-concept:C0011209,
umls-concept:C0014072,
umls-concept:C0033684,
umls-concept:C0035366,
umls-concept:C0085295,
umls-concept:C0302350,
umls-concept:C0851827,
umls-concept:C0927232,
umls-concept:C1274040,
umls-concept:C1280500,
umls-concept:C1513371,
umls-concept:C1701901,
umls-concept:C1707455
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2001-3-12
|
|
pubmed:abstractText |
Experimental allergic encephalomyelitis (EAE) is a CNS autoimmune disease mediated by the action of CD4(+) T cells, macrophages, and proinflammatory cytokines. IL-10 is a cytokine shown to have many anti-inflammatory properties. Studies have shown both inhibition and exacerbation of EAE after systemic IL-10 protein administration. We have compared the inhibitory effect in EAE of Il10 gene delivery in the CNS. Fibroblasts transduced with retroviral vectors expressing IL-10 could inhibit EAE. This was not associated with a prevention of cellular recruitment but an alteration in their phenotype, notably an increase in the numbers of CD8(+) T and B cells. In marked contrast, CNS delivery of adenovirus coding for mouse IL-10 or IL-10 protein performed over a wide dose range failed to inhibit disease, despite producing similar or greater amounts of IL-10 protein. Thus the action of IL-10 may differ depending on the local cytokine microenvironment produced by the gene-secreting cell types.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
166
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4124-30
|
|
pubmed:dateRevised |
2011-11-3
|
|
pubmed:meshHeading |
pubmed-meshheading:11238662-Adenoviridae,
pubmed-meshheading:11238662-Animals,
pubmed-meshheading:11238662-CD4-CD8 Ratio,
pubmed-meshheading:11238662-Cell Line, Transformed,
pubmed-meshheading:11238662-Cell Movement,
pubmed-meshheading:11238662-Down-Regulation,
pubmed-meshheading:11238662-Encephalomyelitis, Autoimmune, Experimental,
pubmed-meshheading:11238662-Fibroblasts,
pubmed-meshheading:11238662-Gene Therapy,
pubmed-meshheading:11238662-Genetic Vectors,
pubmed-meshheading:11238662-Histocompatibility Antigens Class II,
pubmed-meshheading:11238662-Injections, Intraventricular,
pubmed-meshheading:11238662-Injections, Subcutaneous,
pubmed-meshheading:11238662-Interleukin-10,
pubmed-meshheading:11238662-Mice,
pubmed-meshheading:11238662-Mice, Inbred Strains,
pubmed-meshheading:11238662-Nerve Tissue Proteins,
pubmed-meshheading:11238662-Retroviridae,
pubmed-meshheading:11238662-Spinal Cord,
pubmed-meshheading:11238662-Temperature
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system.
|
|
pubmed:affiliation |
Neuroinflammation Group, Department of Neurochemistry, Institutes of Neurology and Ophthalmology, UCL, University of London, London, United Kingdom. jcroxfor@hgmp.mrc.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
